Amedisys [AMED] vs Chemed [CHE] Detailed Stock Comparison

Amedisys Inc.

NASDAQ
Loading...

Chemed Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amedisys Inc. wins in 5 metrics, Chemed Corporation wins in 15 metrics, with 0 ties. Chemed Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amedisys Inc. Chemed Corporation Better
P/E Ratio (TTM) 39.30 20.88 Chemed Corporation
Price-to-Book Ratio 2.69 5.36 Amedisys Inc.
Debt-to-Equity Ratio 35.34 14.68 Chemed Corporation
PEG Ratio -2.78 -2.12 Chemed Corporation
EV/EBITDA 13.74 13.21 Chemed Corporation
Profit Margin (TTM) 3.56% 10.48% Chemed Corporation
Operating Margin (TTM) 11.70% 16.62% Chemed Corporation
EBITDA Margin (TTM) 11.70% 16.62% Chemed Corporation
Return on Equity 6.67% 25.28% Chemed Corporation
Return on Assets (TTM) 6.52% 13.40% Chemed Corporation
Free Cash Flow (TTM) $214.29M $325.48M Chemed Corporation
Dividend Yield N/A 0.56% N/A
1-Year Return 2.68% -23.92% Amedisys Inc.
Price-to-Sales Ratio (TTM) 1.38 2.03 Amedisys Inc.
Enterprise Value $3.48B $5.34B Chemed Corporation
EV/Revenue Ratio 1.45 2.11 Amedisys Inc.
Gross Profit Margin (TTM) 43.96% 35.22% Amedisys Inc.
Revenue per Share (TTM) $73 $176 Chemed Corporation
Earnings per Share (Diluted) $2.57 $18.34 Chemed Corporation
Beta (Stock Volatility) 0.90 0.48 Chemed Corporation
Short % of Float 9.90% 4.26% Chemed Corporation

Amedisys Inc. vs Chemed Corporation Stock Performance Analysis

Loading Price Chart...

AMED
CHE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amedisys Inc.0.00%0.05%3.57%7.76%10.13%10.13%
Chemed Corporation1.00%-3.56%-2.54%6.32%-1.61%-0.07%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amedisys Inc.2.68%-14.45%-58.43%149.36%328.29%215.59%
Chemed Corporation-23.92%-23.30%-10.84%220.84%546.58%704.20%

Performance & Financial Health Analysis: Amedisys Inc. vs Chemed Corporation

MetricAMEDCHE
Market Information
Market Cap i$3.32B$5.65B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,027,642222,026
90 Day Avg. Volume i618,767264,265
Last Close$100.99$423.49
52 Week Range$82.15 - $101.02$365.21 - $562.77
% from 52W High-0.03%-24.75%
All-Time High$325.12 (Jan 25, 2021)$654.62 (Mar 11, 2024)
% from All-Time High-68.94%-35.31%
Growth Metrics
Quarterly Revenue Growth0.05%0.00%
Quarterly Earnings Growth-0.13%-0.15%
Financial Health
Profit Margin (TTM) i0.04%0.10%
Operating Margin (TTM) i0.12%0.17%
Return on Equity (TTM) i0.07%0.25%
Debt to Equity (MRQ) i35.3414.68
Cash & Liquidity
Book Value per Share (MRQ)$37.48$71.44
Cash per Share (MRQ)$10.26$5.41
Operating Cash Flow (TTM) i$239.42M$388.27M
Levered Free Cash Flow (TTM) i$300.69M$246.01M
Dividends
Last 12-Month Dividend Yield iN/A0.56%
Last 12-Month Dividend iN/A$2.30

Valuation & Enterprise Metrics Analysis: Amedisys Inc. vs Chemed Corporation

MetricAMED (Aug 31, 2025)CHE (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i39.3020.88
Forward P/E i19.7614.39
PEG Ratio i-2.78-2.12
Price to Sales (TTM) i1.382.03
Price to Book (MRQ) i2.695.36
Market Capitalization
Market Capitalization i$3.32B$5.65B
Enterprise Value i$3.48B$5.34B
Enterprise Value Metrics
Enterprise to Revenue i1.452.11
Enterprise to EBITDA i13.7413.21
Risk & Other Metrics
Beta i0.900.48
Book Value per Share (MRQ) i$37.48$71.44

Financial Statements Comparison: Amedisys Inc. vs Chemed Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMED (2024)CHE (2025)
Revenue/Sales i2.35B2.53B
Cost of Goods Sold i1.33B1.71B
COGS % of Revenue i56.7%67.5%
Gross Profit i1.02B823.18M
Gross Margin i43.3%32.5%
Research & Development iN/AN/A
Operating Income (EBIT) i209.57M341.16M
Operating Margin i8.9%13.5%
EBITDA i292.47M425.28M
EBITDA Margin i12.5%16.8%
Pre-Tax Income i86.22M355.78M
Pre-Tax Income % of Revenue i3.7%14.1%
Income Tax i48.05M90.54M
Income Tax % of Revenue i2.0%3.6%
Net Income (Profit) i38.16M265.24M
Profit Margin i1.6%10.5%

Balance Sheet & Liquidity Metrics

MetricAMED (2024)CHE (2025)
Cash & Equivalents i303.24M74.52M
Total Current Assets i632.08M302.62M
Total Current Assets % of Revenue i26.9%12.0%
Total Current Liabilities i514.39M287.13M
Total Current Liabilities % of Revenue i21.9%11.3%
Long-Term Debt i395.42M102.87M
Long-Term Debt % of Revenue i16.8%4.1%
Total Shareholders Equity i1.18B979.41M
Retained Earnings i791.16M2.96B
Retained Earnings % of Revenue i33.7%116.8%
Property, Plant & Equipment i167.80M131.15M

Cash Flow Statement Comparison

MetricAMED (2024)CHE (2025)
Operating Cash Flow i144.50M383.11M
Operating Cash Flow % of Revenue i6.2%15.1%
Capital Expenditures i-6.55M4.57M
Free Cash Flow i214.29M325.48M
FCF Margin i9.1%12.9%
Debt Repayment i00
Common Stock Repurchase i-6.15M-431.50M

Short Interest & Institutional Ownership Analysis

MetricAMEDCHE
Shares Short i3.20M487,863
Short Ratio i6.841.62
Short % of Float i9.90%4.26%
Shares Outstanding i32.78M13.71M
Float Shares i32.24M13.53M
% Held by Insiders i1.95%1.87%
% Held by Institutions i96.37%98.39%
% Held by Public i1.68%-0.26%

Dividend Analysis & Yield Comparison: Amedisys Inc. vs Chemed Corporation

MetricAMEDCHE
Last 12-Month Dividend iN/A$2.30
Last 12-Month Dividend Yield iN/A0.56%
3-Year Avg Annual Dividend iN/A$1.93
3-Year Avg Dividend Yield iN/A0.09%
3-Year Total Dividends iN/A$5.78
Ex-Dividend DateN/AFeb 23, 2026